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Lung Cancer
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Rengyun Liu, MS,* Xiaobei Peng, MS,* Zhi-hao Wu, PhD,§ Jun Chen, MD,§ Hongyu Liu, MD,§
Qing-Hua Zhou, MD,§ and Hong-Tao Zhang, PhD*
Purpose: This study aims to explore the association of CpG island
methylator phenotype (CIMP) involving tumor suppressor genes on
short arm of chromosome 3 (3p) with increased risk of non-small
cell lung cancer (NSCLC).
Methods and Materials: In this study, four NSCLC cell lines were
cultured, and peripheral blood mononuclear cell (PBMC) specimens
from 80 patients with NSCLC and 80 matched controls were
collected for 3p-involved CIMP (3pCIMP) analysis. 3pCIMP was
referred to as having at least three synchronously methylated genes
of 3p per sample. Methylation-specific polymerase chain reaction
was performed to examine the methylation status of each gene. DNA
demethylation of NSCLC cell lines was achieved through the
treatment with 5-aza-deoxycytidine. Logistic regression was used to
assess odds ratios and 95% confidence intervals, which were ad-
justed for gender, age, and smoking status.
Results: Demethylation experiment showed that 3pCIMP status
could play an important role in NSCLC cell proliferation. A total of
97.5% of PBMC specimens from NSCLC patients presented pro-
moter methylation of any one of six genes (hOGG1, RAR-B,
SEMA3B, RASSF1A, BLU, or FHIT) on 3p. Interestingly, 3pCIMP
was found in 43.8% of NSCLC PBMC specimens and only in 6.3%
of normal PBMC samples. The data suggest that 3pCIMP status is
significantly associated with NSCLC and normal PBMC samples
(p  0.001). More importantly, the results show that 3pCIMP
positive carriers have a 12.8-fold increased risk of NSCLC (adjusted
odds ratio, 12.8; 95% confidence interval, 4.38–37.4, p  0.001) in
Chinese population.
Conclusions: This is the first evidence of an association between
PBMC 3pCIMP and risk for NSCLC.
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(J Thorac Oncol. 2010;5: 790–797)
Epidemiological evidence has documented that lung cancerhas markedly increased incidence and mortality over the
past decade in China.1 Because at least 75% of patients with
lung cancer have evidence of regional or distant metastasis at
the time of diagnosis, the overall 5-year survival rate of lung
cancer is very poor.2 Non-small cell lung cancer (NSCLC) is
the most common type of lung cancer, accounting for ap-
proximately 85% of all lung cancer cases and consisting
mainly of adenocarcinoma, squamous cell carcinoma, and
large cell carcinoma.3 It has been suggested that NSCLC
could result from accumulation of multiple genetic or epige-
netic changes, including DNA methylation and histone acet-
ylation4 and microRNA.5,6 Our recent studies provide support
for the notion that DNA methylation could underlie epige-
netically inactivation of tumor suppressor genes (TSGs) on
short arm of chromosome 3 (3p) in NSCLC,7 and CpG island
methylator phenotype (CIMP) involving TSGs on 3p could
be one of the frequent epigenetic events in carcinogenesis of
NSCLC.8
Multiple investigations have evaluated DNA methyl-
ation changes present in NSCLC, elucidating a wide range of
methylation frequencies for a variety of genes.9–13 A majority
of studies have compared the methylation aberrations oc-
curred in NSCLC with those presented in the paired paracan-
cerous lung tissues from the same patient.14 More recently,
Brock et al.15 found aberrant patterns of promoter methyl-
ation of APC, RASSF1A, p16, and CDH13 associated with
early recurrence in stage I NSCLC. Taken together, these
experimental data are beneficial in identifying a panel of
cancer-specific methylation markers for early detection and
prevention and targeted treatment of NSCLC. Importantly,
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more particular attention was paid to assessing synchronous
methylation of multiple cancer-related genes (termed CIMP)
and its implications to patients with NSCLC.16,17
Following the recently published reports on the pres-
ence of CIMP in NSCLC,16,17 for the first time, we shed light
on the presence of chromosome 3p-involved CIMP
(3pCIMP) that might play an important role in tumorigenesis
of NSCLC.8 Although there is accumulating evidence sug-
gesting that somatic epigenetic changes of putative TSGs
contribute to carcinogenesis of NSCLC14 and DNA hyper-
methylation frequently occurs in peripheral blood mononu-
clear cell (PBMC) from colorectal and lung cancer pa-
tients,18,19 little is known about an association of PBMC
3pCIMP with the predisposition to developing NSCLC.
In this study, we tested hypothesis that some individu-
als carrying PBMC 3pCIMP are more susceptible to devel-
oping NSCLC. First, to investigate whether 3pCIMP status
could play an important role in NSCLC cell proliferation, we
examined 3pCIMP status in four NSCLC cell lines before and
after the demethylating treatment. Then, we subjected bisul-
fite-modified DNA of PBMC from 80 NSCLC patients and
80 controls to analysis of 3pCIMP status. The results suggest
that 3pCIMP could occur frequently in PBMC from Chinese
population, indicating that PBMC 3pCIMP plays an impor-
tant role in predisposition to NSCLC.
METHODS
NSCLC Cell Lines and Specimens
Four NSCLC cell lines (SPC-A-1, A549, 95-D, and
LTEP-a-2) purchased from Shanghai Institute of Biochemis-
try and Cell Biology were cultured in Roswell Park Memorial
Institute (RPMI) 1640 medium (Gibco-Invitrogen Inc.) with
10% fetal bovine serum (Gibco-Invitrogen Inc., Grand Island,
NY) and incubated at 37°C in a humid atmosphere of 5% CO2.
These NSCLC cell lines are from lung adenocarcinoma cells.
A total of 80 blood specimens were obtained after
informed consent from patients who were diagnosed as pri-
mary NSCLC in the First Affiliated Hospital of Soochow
University between January 2005 and March 2008. Patho-
logic stages for NSCLC patients were determined according
to the Revised International System for Staging Lung Can-
cer.20 None of NSCLC patients had received either radiother-
apy or chemotherapy before blood sampling. In addition to
NSCLC blood samples, 80 blood samples were also collected
from individuals with no history of cancer as controls, which
were randomly selected from the same geographic region,
and their ages were in the similar range as the cancer patients.
This research was approved to perform by the Academic
Advisory Board of Soochow University.
PBMC was isolated by centrifugation at 3500 rpm
for 20 minutes after blood sampling.21 Genomic DNA was
isolated from NSCLC cell lines and the samples according
to standard proteinase K digestion and phenol-chloroform
extraction.
Bisulfite Modification
Genomic DNA was treated with sodium bisulfite before
methylation analysis according to the CpGenome Fast DNA
Modification Kit (Chemicon International, Inc.). The proce-
dure for bisulfite modification was described in our previ-
ously published article.8 Briefly, 1.0 g of DNA in a volume
of 100 l water were denatured for 10 minutes at 37°C by
addition of 7 l of freshly prepared 3 M NaOH. Then 550 l
of freshly prepared DNA Modification Reagent (pH 5.0) was
added and mixed well. The mixture was incubated at 55°C for
20 hours. After adding 750 l of binding buffer, we purified
the modified DNA with spin columns. Desulphonation was
completed on the column by addition of 50 l of freshly
prepared 20 mM NaOH/90% EtOH. Finally, DNA was eluted
with 30 to 45 l of elution buffer and stored at 20°C until
analyzing.
Methylation-Specific PCR
DNA methylation was determined using methyla-
tion-specific polymerase chain reaction (PCR) (MSP) de-
scribed elsewhere.22 MSP can differentiate methylated
alleles from unmethylated ones of an interested gene after
treatment with sodium bisulfite. Primer sequences for MSP
analysis of RAR-B, SEMA3B, RASSF1A, BLU, and FHIT
were reported previously23–27 except for that of hOGG1
was designed by ourselves using Methyl Primer Express
Software version 1.0 (Applied Biosystem Inc, Forster City,
CA).8 All the cycling conditions of PCR consisted of an
initial denaturation at 95°C for 5 minutes, followed by 35
cycles of 94°C for 30 seconds, various annealing temper-
ature for 45 seconds, and 72°C for 1 minute 15 seconds.
The expected PCR products were revealed by electro-
phoresis and visualized with ethidium bromide staining.
SPC-A-1 and A549 NSCLC cell lines were used as posi-
tive controls for hOGG1, RAR-B, SEMA3B, BLU, and
FHIT; and for RASSF1A, respectively. But distilled water
and unbisulfited DNA were served as negative controls.7
DNA Demethylation of NSCLC Cell Lines
DNA demethylation was performed on NSCLC cells by
treatment with 5-aza-deoxycytidine (5-aza-CdR) (Sigma-Al-
drich Inc, St. Louis, MO). Briefly, NSCLC cells were seeded
at a density of 5  104 cells in RPMI 1640 containing 10%
fetal bovine serum on day 1 and allowed to grow under
standard tissue culture conditions. On days 2, 4, and 6, the
medium was changed to serum-free RPMI 1640 containing 5
M 5-aza-CdR. On days 3, 5, and 7, the medium was
changed to drug-free and serum-free RPMI 1640. On days 1,
5, and 7, the cells were harvested for analysis of DNA
methylation.
MTT Assay
Proliferation of NSCLC cells before and after treatment
of demethylation agent 5-aza-CdR was assessed with the
MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide] (Sigma- Aldrich, Inc) method. Cells were seeded in
96-well plates at a density of 5  104 cells/well and cultured
under standard tissue culture conditions for 24 hours. On days
2, 4, and 6, the medium was changed to serum-free RPMI
1640 containing 5 M 5-aza-CdR. On days 1, 5, and 7, 20 l
of 5 mg/ml MTT were added, and the cells were incubated for
5 hours at 37°C. One hundred microliters of dimethyl sulfox-
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ide were quickly added to all wells and mixed thoroughly, so
that the dark blue crystals dissolved effectively. Absorbance
was measured at the wavelength of 550 nm. This experiment
was repeated three times. All data represent the mean of nine
wells, which were subjected to statistical analysis.
Definition of CIMP
According to the previously reported CIMP, which was
defined by average of number of methylated genes per tu-
mor,28,29 we classified it into two categories, including CIMP
positive with at least three methylated genes and CIMP
negative with less than three methylated genes.
Statistical Analysis
Chi-square test and Fisher exact test were used to
evaluate the correlation between two different categories.
Logistic regression was performed to assess odds ratios
(ORs) and 95% confidence intervals, which were adjusted for
gender, age, and smoking status, using STATA version 10.0
software package (StataCorp LP, College Station, TX). The
sensitivity, specificity, positive predictive value, and accu-
racy for hOGG1, SEMA3B, RASSF1A, and 3pCIMP were
calculated using the 2  2 contingency table. Statistical
differences were considered to be significant at p  0.05.
Data analysis was performed using SigmaStat software (Systat
Software, San Jose, CA) and SPSS version 11.5 software pack-
age (SPSS Inc, Chicago, IL).
RESULTS
Relationship Between 3pCIMP and NSCLC Cell
Proliferation
To determine whether 3pCIMP plays an important
role in the proliferation of NSCLC cells, we performed
DNA demethylation and MTT analyses and 3pCIMP eval-
uation on four NSCLC cell lines. As illustrated in Figure 1,
SPC-A-1 and A549 presented 3pCIMP positive before
(day 1) and after (days 5 and 7) treatment of demethylation
agent 5-aza-CdR, respectively. However, 95-D and LTEP-
a-2 showed 3pCIMP negative after (day 7) 5-aza-CdR
treatment, albeit that they presented 3pCIMP positive after
(day 5) demethylation treatment.
Meanwhile, we examined the effect of demethylation
treatment on cell proliferation in these NSCLC cell lines. As
shown in Figure 2, cell proliferation was significantly de-
creased in 95-D and LTEP-a-2 on day 7, but not in SPC-A-1
and A549. These findings were compatible with 3pCIMP
evaluation (Figure 1), indicating that 3pCIMP status could
play an important role in NSCLC cell proliferation. 5-aza-
CdR treatment is a currently accepted system to investigate
effects of hypomethylation, although this compound is rec-
ognized to be capable of inducing other cellular effects.30
Methylation Profile of Multiple Genes on 3p in
PBMC From NSCLC Patients
Methylation profile for PBMC specimens from 80
NSCLC patients and 80 controls was determined using MSP
method for six TSGs on 3p, including hOGG1, RAR-B,
SEMA3B, RASSF1A, BLU, and FHIT. Representative bands
for MSP analysis were exemplified in Figure 3, and the
detailed frequency distribution of aberrant methylation for
each gene was seen in Figure 4. With respect to NSCLC, the
frequency of promoter methylation of the gene was 22.5% for
hOGG1, 20.0% for RAR-B, 91.3% for SEMA3B, 20.0% for
RASSF1A, 48.8% for BLU, and 23.8% for FHIT, respectively.
By contrast, lower frequencies of methylation for hOGG1
(7.5%), RAR-B (8.8%), SEMA3B (47.5%), and RASSF1A
FIGURE 2. Cell proliferation analysis for non-small cell lung
cancer (NSCLC) cell lines without and with treatment of de-
methylation agent 5-aza-CdR. The cells were grown to 80%
confluency when they were harvested on day 7. The y-axis
represents the absorbance of 550 nm wavelength of MTT
assay. Symbols  and  below 5-aza-CdR represent without
and with treatment, respectively. On day 7, significant differ-
ence in cell proliferation was observed between NSCLC cell
lines (95-D and LTEP-a-2) without and with 5-aza-CdR treat-
ment. *p  0.05.
FIGURE 1. 3p-involved CpG island methylator phenotype
(3pCIMP) in four non-small cell lung cancer (NSCLC) cell
lines without and with treatment of demethylation agent
5-aza-CdR. The variable day represents cell harvest schedule.
On day 7, two NSCLC cell lines (SPC-A-1 and A549) with
3pCIMP have methylation of at least three genes, and two
NSCLC cell lines (95-D and LTEP-a-2) with 3pCIMP present
methylation of less than three genes. Symbols  and  be-
low 5-aza-CdR represent without and with treatment, re-
spectively. Black boxes, presence of unmethylation and meth-
ylation; white boxes, presence of unmethylation. Symbols 
and  below CIMP represent CIMP negative and positive,
respectively.
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FIGURE 3. The representative patterns of methyl-
ated (M) and unmethylated (U) alleles in methyla-
tion-specific polymerase chain reaction (MSP) analy-
sis for six genes in peripheral blood mononuclear
cell from patients with non-small cell lung cancer
(NSCLC). Two samples (2CB and 48CB) with CpG
island methylator phenotype (CIMP) have methyl-
ation of at least three genes. Two samples (4CB and
28CB) with CIMP present methylation of less than
three genes. MSP analysis of SPC-A-1 and A549
NSCLC cell lines served as a positive control (Pos)
for hOGG1, RAR-B, SEMA3B, BLU, and FHIT; and for
RASSF1A, respectively. Distilled water and unbisul-
fited DNA were used as negative controls (Neg 1
and Neg 2, respectively).
FIGURE 4. Summary of methyl-
ation for hOGG1, RAR-B, SEMA3B,
RASSF1A, BLU, and FHIT in PBMC
from 80 patients with NSCLC (A)
and 80 controls (B). Green boxes,
presence of unmethylation; yellow
boxes, presence of unmethylation
and methylation. CB, cancer blood
sample; NB, normal blood sample;
, CIMP positive; , CIMP nega-
tive; PBMC, peripheral blood mono-
nuclear cell; NSCLC, non-small cell
lung cancer.
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(2.5%) were found in controls. A significant difference in
methylation status for hOGG1, SEMA3B, and RASSF1A was
found between PBMC from NSCLC patients versus PBMC
from controls (p  0.02, p  0.001, and p  0.001, respec-
tively) (Figure 5).
Frequency of 3pCIMP in PBMC From NSCLC
Patients and Normal Blood Samples
A total of 97.5% (78 of 80) of PBMC specimens from
NSCLC patients presented promoter methylation of any one
of six genes (hOGG1, RAR-B, SEMA3B, RASSF1A, BLU, or
FHIT) on 3p. Correspondingly, a total of 77.5% (62 of 80) of
normal blood samples had at least one gene methylated
(Figure 4). A total of 26.3% (21 of 80) of NSCLC carried one
gene, 27.5% (22 of 80) carried two genes, 32.5% (26 of 80)
carried three genes, 10% (8 of 80) carried four genes, and
1.25% (1 of 80) carried five genes methylated (Figure 6).
Correspondingly, a total of 33.8% (27 of 80) of normal blood
samples had one gene, 37.5% (30 of 80) had two genes, 3.8%
(3 of 80) had three genes, and 2.5% (2 of 80) had four genes,
and none had five genes methylated (Figure 6). More impor-
tantly, 3pCIMP was observed in 43.8% (35 of 80) of
NSCLC PBMC and 6.3% (5 of 80) of normal blood samples;
3pCIMP- was found in 56.2% (45 of 80) of NSCLC PBMC
and 93.7% (75 of 80) of normal blood samples (Table 1).
Using a chi-square test statistical analysis, we found that
3pCIMP status was significantly associated with NSCLC and
normal blood samples (2df  128.0, p  0.001).
3pCIMP of PBMC in Association with Increased
Risk for NSCLC
In this study, we examined the relation of 3pCIMP
status to clinical characteristics of NSCLC (Table 2). As a
result, no significant association between 3pCIMP status and
multiple clinical factors, including age, sex, smoking history,
differentiation, tumor node metastasis stage, and histologic
stratification was found (p 0.05). To determine whether the
presence of 3pCIMP has an effect on increased risk of
NSCLC, we performed logistic regression to assess the ORs
in the paired cohort. Consequently, methylation of hOGG1,
SEMA3B, and RASSF1A, the gene pair hOGG1 and SEMA3B,
hOGG1 and RASSF1A, and SEMA3B and RASSF1A was
observed to increase significantly risk of NSCLC when com-
pared with methylation-free ones (3.72-fold, p  0.02; 7.97-
fold, p  0.001; 4.49-fold, p  0.001; 9.95-fold, p  0.001;
infinite folds, p  0.02; 10.00-fold, p  0.001, respectively).
More intriguingly, we found that 3pCIMP positive carriers
had a 12.79-fold increased risk of developing NSCLC (ad-
justed OR, 12.8; 95% confidence interval, 4.38–37.4, p 
0.001) in Chinese population (Table 3).
Given that these DNA methylation marker candidates
(listed in Table 4) seem to associate preferentially with
increased risk of NSCLC in Chinese population, we com-
pared the differences in their sensitivity and specificity for
diagnosis of NSCLC. As summarized in Table 4, the speci-
FIGURE 5. Frequency of methylation for six genes in pe-
ripheral blood mononuclear cell from 80 patients with non-
small cell lung cancer (NSCLC) and 80 controls. Significantly
methylated difference of hOGG1, SEMA3B, and RASSF1A was
observed between NSCLCs and controls (*p  0.02, p 
0.001, and p  0.001, respectively).
FIGURE 6. Methylated gene numbers per sample in 80
non-small cell lung cancers and 80 normal blood samples.
TABLE 1. Characteristics of NSCLC Cases and Controls by
Age, Sex, Smoking History, and 3pCIMP Status
Variable
Cases
(n  80)
Controls
(n  80) pa
Age (yr), mean  SD) 61.0  10.3 60.7  10.7 0.83
Sex
Male 59 (73.8) 50 (62.5) 0.18
Female 21 (26.2) 30 (37.5)
Smoking history
Yes 47 (58.7) 19 (23.8) 0.001
No 33 (41.3) 61 (76.2)
CIMP status
3pCIMP 35 (43.8) 5 (6.3) 0.001
3pCIMP 45 (56.2) 75 (93.7)
Values are expressed as n (%).
NSCLC, non-small cell lung cancer; 3pCIMP, 3p-involved CpG island methylator
phenotype.
a 2 test.
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ficity for SEMA3B (52.5%) and its combinations (47.5% and
52.5%) was much lower than hOGG1 (92.5%), RASSF1A
(97.5%), the gene pair hOGG1 and RASSF1A (90.0%), and
3pCIMP (93.8%), although the sensitivity for SEMA3B
(91.3%) and its combinations (92.5% and 91.3%) was much
higher than hOGG1 (22.5%), RASSF1A (20.0%), the gene
pair hOGG1 and RASSF1A (32.5%), and 3pCIMP (43.8%).
Moreover, the positive predictive value and overall accuracy
for 3pCIMP (87.5% and 68.8%) were relatively higher com-
pared with a majority of DNA methylation marker candi-
dates. Taken together, 3pCIMP ranks first among these po-
tential DNA methylation markers for NSCLC carcinogenesis.
DISCUSSION
Reliable markers for NSCLC are still lacking, even
though more efforts on discovering them have been made.6
Improved understanding of molecular events, including epi-
genetic silencing of genes, may help to identify a panel of
early tumor markers.31,32 Epigenetic silencing of TSGs via
promoter hypermethylation has been found to correlate with
the initiation and progression of various types of cancers,
including lung cancer.33,34 3p may harbor multiple TSGs,
which are involved in the early stages of bronchial carcino-
genesis.35 However, no evidence for association of PBMC
epigenetic changes regarding TSGs on 3p with increased risk
of NSCLC has been reported. Therefore, in this study, we
focused on identifying the presence of 3pCIMP in NSCLC
PBMC and assessing an association between PBMC 3pCIMP
and the predisposition to NSCLC.
In an effort to validate first the biologic function of
3pCIMP, we performed MTT, 3pCIMP and demethylation
analyses in four NSCLC cell lines and found different
3pCIMP status (either positive or negative) compatible with
differentiately proliferated changes of NSCLC cells (either
preserved or decreased), suggesting that 3pCIMP could func-
tion as an epigenetic silencing of TSGs in pathogenesis of
NSCLC. These findings are consistent with those from our
recently available study8 of NSCLC tissues that noted a
significant association between somatic 3pCIMP and devel-
opment of NSCLC. Given the fact that methylated status of a
CpG site is more stably inherited than unmethylated status36
and that the best-known epigenetic marker is DNA methyl-
TABLE 2. Association Between 3pCIMP Status of PBMC
and Clinical Characteristics of NSCLC
Variable Cases
3pCIMP
(n  35)
3pCIMP
(n  45) pa
Age (yr), mean  SD 61  11.3 61.0  9.6 1.00
Sex
Male 59 22 37 0.09
Female 21 13 8
Smoking history
Yes 47 17 30 0.16
No 33 18 15
Differentiation
Well 3 1 2 0.58
Moderate 41 16 25
Low 36 18 18
TNM stage
Stage I 26 10 16 0.74
Stage II 34 15 19
Stage III  IV 20 10 10
Histology
AC 22 12 10 0.13
SCC 37 14 23
LCC 10 2 8
ACC 8 6 2
Carc 3 1 2
a 2 test.
AC, adenocarcinoma; SCC, squamous cell carcinoma; LCC, large cell carcinoma;
ACC, alveolar cell carcinoma; Carc, carcinoid carcinoma; NSCLC, non-small cell lung
cancer; 3pCIMP, 3p-involved CpG island methylator phenotype.
TABLE 3. Methylation Status of Six Genes Located on
Chromosome 3p Among NSCLC Patients and Controls and
Their Contributions to the Risk for NSCLC
Cases
(N  80),
n (%)
Controls
(N  80),
n (%) p OR (95% CI)a
hOGG1
U 62 (77.5) 74 (92.5) 1.00
M 18 (22.5) 6 (7.5) 0.02 3.72 (1.07–12.9)
RAR-B
U 64 (80.0) 73 (91.3) 1.00
M 16 (20.0) 7 (8.7) 0.07 2.24 (0.67–7.51)
SEMA3B
U 7 (8.7) 42 (52.5) 1.00
M 73 (91.3) 38 (47.5) 0.001 7.97 (3.01–21.1)
RASSF1A
U 64 (80.0) 78 (97.5) 1.00
M 16 (20.0) 2 (2.5) 0.001 4.49 (0.90–22.3)
BLU
U 41 (51.2) 47 (58.8) 1.00
M 39 (48.8) 33 (41.2) 0.43 1.31 (0.59–2.90)
FHIT
U 61 (76.2) 61 (76.2) 1.00
M 19 (23.8) 19 (23.8) 1.00 1.37 (0.52–3.56)
hOGG1 and SEMA3B
USM 63 (78.8) 78 (97.5) 1.00
SM 17 (21.2) 2 (2.5) 0.001 9.95 (2.11–46.9)
hOGG1 and RASSF1A
USM 75 (93.8) 80 (100) 1.00
SM 5 (6.2) 0 (0.0) 0.02 Infinite (1.36-)
SEMA3B and RASSF1A
USM 64 (80.0) 78 (97.5) 1.00
SM 16 (20.0) 2 (2.5) 0.001 10.0 (2.11–47.5)
3pCIMP status
3pCIMP 45 (56.2) 75 (93.7) 1.00
3pCIMP 35 (43.8) 5 (6.3) 0.001 12.8 (4.38–37.4)
a ORs and 95% CIs were calculated in a logistic regression model and adjusted for
age, sex, and smoking status.
NSCLC, non-small cell lung cancer; OR, odds ratio; CI, confidence interval; U,
unmethylated; M, methylated; USM, unsynchronously methylated; SM, synchronously
methylated.
Journal of Thoracic Oncology • Volume 5, Number 6, June 2010 Association of 3p CpG Island Methylator Phenotype and NSCLC
Copyright © 2010 by the International Association for the Study of Lung Cancer 795
ation,37 we hypothesize that 3pCIMP might be emerging as a
promising risk factor of NSCLC.
On the basis of what we observed earlier, additional
studies are needed to address the question of whether
3pCIMP could contribute to increased risk of developing
NSCLC. By using a population-based investigation, we found
that the frequency of PBMC methylation for six TSGs pro-
moter ranged from 20.0% for RAR-B (or RASSF1A) to 91.3%
for SEMA3B. Although 3p TSG methylation is frequent in
NSCLC PBMC, we cannot exclude the possibility that the
detected TSG methylation is derived from circulating tumor
cells in the peripheral blood. As summarized in our recently
published article in Lung Cancer,8 the frequencies of meth-
ylation for hOGG1, RAR-B, SEMA3B, RASSF1A, BLU, and
FHIT in 60 NSCLC tumors are 65%, 50%, 57%, 67%, 65%,
and 47%, respectively, showing that the methylation fre-
quency for hOGG1, RAR-B, RASSF1A, BLU, and FHIT was
far lower in NSCLC PBMC than paired NSCLC tissues.
Especially, the frequency for VHL and hMLH1 that were not
considered as contributing to PBMC 3pCIMP was zero in all
subjects, including NSCLC patients and controls (data not
shown). Despite of discrepant frequencies between our report
and Seng et al. (hMLH1 in 12.0% and 35.7% of NSCLC
tumors, respectively),8,38 the results suggested that hMLH1
methylation could be a late event in NSCLC progression.
More importantly, 3pCIMP was found in 43.8% of NSCLC
PBMC specimens but only in 6.3% of normal PBMC sam-
ples. More excitingly, 3pCIMP-positive carriers have a 12.8-
fold increased risk of developing NSCLC in Chinese popu-
lation, and combined analysis with sensitivity and specificity
has shown that 3pCIMP might become preferentially a sur-
rogate for other DNA methylation marker candidates of
NSCLC, including hOGG1, SEMA3B, and RASSF1A.
Although CIMP etiology remains elusive, it exists in
several malignant solid tumors.16 Meanwhile, the correlation
of CIMP with clinicopathologic factors in various human
cancers was well established.39–41 However, we did not find
an association between 3pCIMP and multiple clinical factors,
including age, sex, smoking history, differentiation, tumor
node metastasis stage, and histologic stratification of NSCLC,
which was in accordance with the data from Suzuki et al.17
The results demonstrate that 3pCIMP could be in relation to
NSCLC initiation rather than progression. Considering that
treatment with demethylating agents can restore gene expres-
sion of inactivating TSGs,42 administration of demethylating
agents may become an ideal candidate for individuals with
3pCIMP positive to decrease risk of developing NSCLC.
In conclusion, we provide strong evidence of an asso-
ciation between PBMC 3pCIMP and risk for NSCLC, which
supports the suggestion from Russo et al.19 that peripheral
lymphocytes could potentially be used as a surrogate for
bronchial epithelial cells to detect altered DNA methylation
in development and progression of lung cancer. Better un-
derstanding of 3pCIMP may provide new insight into cancer
prevention and therapeutic interventions.
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